Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $49.4 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $49.4 million, down 9.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.4 million (down 9.87% YoY), and the FY2025 annual result was $46.2 million, down 44.3% from the prior year.
• Current Deferred Revenue came in at $49.4 million for Q1 2026 at Adaptive Biotechnologies, up from $46.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $155.0 million in Q2 2022 to a low of $41.3 million in Q3 2025.
• The 5-year median for Current Deferred Revenue is $57.9 million (2023), against an average of $70.1 million.
• Across the five-year window, Current Deferred Revenue jumped 85.55% in 2022 and tumbled 62.64% in 2023, its largest moves.
• Adaptive Biotechnologies' Current Deferred Revenue stood at $64.1 million in 2022, then slipped by 24.15% to $48.6 million in 2023, then jumped by 70.56% to $82.9 million in 2024, then plunged by 44.3% to $46.2 million in 2025, then increased by 6.92% to $49.4 million in 2026.
• The last three Current Deferred Revenue figures came in at $49.4 million (Q1 2026), $46.2 million (Q4 2025), and $41.3 million (Q3 2025), per Business Quant data.